Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · see citing works

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250 · see citing works

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hogendoorn, P. C. W., Athanasou, N. A., Bielack, S., de Álava, E., Tos, A. P. D., Ferrari, S., Gelderblom, H. A. J., Grimer, R. J., Hall, K. S., Hassan, A. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 716 · see citing works

Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · see citing works

The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas

Hernando, E., Charytonowicz, E., Dudas, M. E., Menéndez, S., Matushansky, I., Mills, J. E., Socci, N. D., Behrendt, N., Ma, L., Maki, R. G., et al. (2007) · Nature Medicine · doi:10.1038/nm1560 · Cited by 288 · see citing works

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Mita, M. M., Mita, A. C., Chu, Q. S.-C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273 · see citing works

Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Bielack, S., Carrle, D., & Casali, P. G. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp154 · Cited by 272 · see citing works

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Kibel, A. S. (2009) · Yearbook of Urology · doi:10.1016/s0084-4071(09)79253-x · Cited by 266 · see citing works

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Casali, P. G., & Blay, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq209 · Cited by 256 · see citing works

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D’Amato, G. Z., Blay, J., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 244 · see citing works

Constant allelic alteration on chromosome 16p ( TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma

Pan, C., Chung, M., Ng, K. F., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2289 · Cited by 221 · see citing works

Updates of mTOR Inhibitors

Zhou, H., Luo, Y., & Huang, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010793498663 · Cited by 181 · see citing works

ATP-Competitive Inhibitors of mTOR: An Update

Schenone, S., Brullo, C., Musumeci, F., Radi, M., & Botta, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391651 · Cited by 142 · see citing works

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

Rivera, V. M., Squillace, R. M., Miller, D., Berk, L., Wardwell, S., Ning, Y., Pollock, R. M., Narasimhan, N. I., Iuliucci, J. D., Wang, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0792 · Cited by 107 · see citing works

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Hartford, C. M., Desai, A. A., Janisch, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2076 · Cited by 88 · see citing works

EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors

Dobashi, Y., Suzuki, S., Sato, E., Hamada, Y., Yanagawa, T., & Ooi, A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.104 · Cited by 79 · see citing works

Enhancing mTOR-targeted cancer therapy

Wang, X., & Sun, S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903225008 · Cited by 58 · see citing works

Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)

Mita, M. M., Britten, C. D., Poplin, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3509 · Cited by 57 · see citing works

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

Squillace, R. M., Miller, D. F., Cookson, M. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0273 · Cited by 45 · see citing works

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

Targeting the translation machinery in cancer

Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · see citing works

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481 · see citing works

mTOR: Role in cancer, metastasis and drug resistance

Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483 · see citing works

Sarcoma treatment in the era of molecular medicine

Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319 · see citing works

Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology

Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248 · see citing works

mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>

Morrow, J. J., Mendoza, A., Koyen, A., Lizardo, M. M., Ren, L., Waybright, T. J., Hansen, R. J., Gustafson, D. L., Zhou, M., Fan, T. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0326 · Cited by 27 · see citing works

Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (<scp>CanSaRCC</scp>) study

Peretz Soroka, H., Vora, T., Noujaim, J., Marcoux, N., Cohen‐Gogo, S., Alcindor, T., Holloway, C., Rodrigues, C., Karachiwala, H., Alvi, S., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6515 · Cited by 17 · see citing works

Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή

Κοτσόβολης, Γ. (2014) · doi:10.12681/eadd/34564

Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo

Schafer, S. M., Colloca, L., & Wager, T. D. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2014.12.008 · Cited by 117 · see citing works

A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia

Vase, L., Riley, J. L., & Price, D. D. (2002) · Pain · doi:10.1016/s0304-3959(02)00205-1 · Cited by 434 · see citing works

Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks

Kam-Hansen, S., Jakubowski, M., Kelley, J. M., Kirsch, I., Hoaglin, D. C., Kaptchuk, T. J., & Burstein, R. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006175 · Cited by 399 · see citing works

Gender Differences in Placebo Analgesia: Event-Related Potentials and Emotional Modulation

Aslaksen, P. M., Bystad, M., Vambheim, S. M., & Flaten, M. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182080d73 · Cited by 114 · see citing works